(Q37882461)

24 August 2017

1 reference

title

Active surveillance in prostate cancer: the need to standardize (English)

1 reference

24 August 2017

Xavier Filella

1

1 reference

24 August 2017

Juan Alcover

series ordinal

2

1 reference

24 August 2017

Rafael Molina

series ordinal

3

1 reference

24 August 2017

publication date

28 May 2011

1 reference

24 August 2017

1 reference

24 August 2017

volume

32

1 reference

24 August 2017

issue

5

1 reference

24 August 2017

page(s)

839-843

1 reference

24 August 2017

cites work

Global cancer statistics

1 reference

https://api.crossref.org/works/10.1007%2FS13277-011-0193-2

Screening and prostate-cancer mortality in a randomized European study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-011-0193-2

Insignificant prostate cancer and active surveillance: from definition to clinical implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-011-0193-2

Updated nomogram to predict pathologic stage of prostate cancer given prostate-specific antigen level, clinical stage, and biopsy Gleason score (Partin tables) based on cases from 2000 to 2005

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-011-0193-2

EAU guidelines on prostate cancer. Part 1: screening, diagnosis, and treatment of clinically localised disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-011-0193-2

Trends in reporting Gleason score 1991 to 2001: changes in the pathologist's practice

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-011-0193-2

Prostate cancer and the Will Rogers phenomenon.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-011-0193-2

The 2005 International Society of Urological Pathology (ISUP) Consensus Conference on Gleason Grading of Prostatic Carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-011-0193-2

Prostate cancer specific mortality and Gleason 7 disease differences in prostate cancer outcomes between cases with Gleason 4 + 3 and Gleason 3 + 4 tumors in a population based cohort

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-011-0193-2

Clinical impact of new prostate-specific antigen WHO standardization on biopsy rates and cancer detection

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-011-0193-2

Interchangeability of measurements of total and free prostate-specific antigen in serum with 5 frequently used assay combinations: an update.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-011-0193-2

Different prostate-specific antigen assays give different results on the same blood sample: an obstacle to recommending uniform limits for prostate biopsies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-011-0193-2

Natural History of Early, Localized Prostate Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-011-0193-2

Quality requirements and control: EGTM recommendations. European Group on Tumour Markers

21 January 2018

1 reference

12 December 2020

Feasibility study: watchful waiting for localized low to intermediate grade prostate carcinoma with selective delayed intervention based on prostate specific antigen, histological and/or clinical progression.

1 reference

12 December 2020

Prognostic significance of Gleason score 3+4 versus Gleason score 4+3 tumor at radical prostatectomy

1 reference

12 December 2020

Discordance of assay methods creates pitfalls for the interpretation of prostate-specific antigen values.

1 reference

12 December 2020

Prospective validation of active surveillance in prostate cancer: the PRIAS study

1 reference

12 December 2020

Low-risk prostate cancer can and should often be managed with active surveillance and selective delayed intervention

1 reference

12 December 2020

Overdiagnosis Due to Prostate-Specific Antigen Screening: Lessons From U.S. Prostate Cancer Incidence Trends

1 reference

12 December 2020

Primary Gleason pattern as a predictor of disease progression in gleason score 7 prostate cancer: a multivariate analysis of 823 men treated with radical prostatectomy

1 reference

12 December 2020

Critical assessment of tools to predict clinically insignificant prostate cancer at radical prostatectomy in contemporary men

1 reference

12 December 2020

Active Surveillance for Prostate Cancer: Patient Selection and Management

1 reference

12 December 2020

Latest results from the UK trials evaluating prostate cancer screening and treatment: The CAP and ProtecT studies

1 reference

12 December 2020

Intermethod differences in results for total PSA, free PSA, and percentage of free PSA

1 reference

12 December 2020

Evidence to support a continued stage migration and decrease in prostate cancer specific mortality

1 reference

12 December 2020

Geographic pathology of latent prostatic carcinoma

1 reference

12 December 2020

European Association of Urology Position Statement on Screening for Prostate Cancer

1 reference

12 December 2020

PSA doubling time of prostate carcinoma managed with watchful observation alone

1 reference

12 December 2020

Prognostic factors for survival of patients with pathological Gleason score 7 prostate cancer: differences in outcome between primary Gleason grades 3 and 4

1 reference

12 December 2020

10.1007/S13277-011-0193-2

Identifiers

DOI

1 reference

24 August 2017

1 reference